Current therapies for NSCLC patients include tyrosine kinase inhibitors such as erlotinib in the presence of an EGFR mutation, or ALK tyrosine kinase inhibitors, crizotinib, ceritinib, and alectinib against EML4-ALK fusions [36]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.